Drugs / Peginterferon-α2a
Peginterferon-α2a
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02175966 | Jul 2014 → Jan 2015 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01463956 | Jan 2012 → Jun 2014 | chronic hepatitis C virus infection, cirrhosis of liver | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT01277601 | Apr 2011 → Aug 2014 | chronic hepatitis B virus infection | Gilead Sciences | Completed | Met primary |
| Phase 4 | NCT00881582 | Jan 2009 → Dec 2011 | chronic hepatitis C virus infection | King Abdulaziz Medical City | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02381379 Comparator | Mar 2015 → Oct 2018 | chronic myeloid leukemia | Ministry of Health, Malaysia | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2024-06-06 | Gilead Sciences | Results Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA gilead.com ↗
Data Published in NEJM Demonstrate 46% of Patients Taking Bulevirtide 10 mg with PegIFN Achieved Post-Treatment Undetectable HDV RNA at Week 24 |
| 2024-05-22 | Gilead Sciences | Results Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024 gilead.com ↗
Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver |
| 2013-02-04 | Gilead Sciences | Results Gilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir for Hepatitis C gilead.com ↗
All common adverse events (≥10 percent in any group) occurred more frequently in subjects receiving peg-IFN and RBV as compared to sofosbuvir and RBV. |
| 2011-03-31 | Bristol-Myers Squibb | Results Investigational Direct-Acting Antiviral BMS-790052 Plus PEG-Interferon Alfa and Ribavirin Achieved Up to 92% Sustained Virologic Response in Phase II Dose-Ranging Study of Treatment-Naïve Hepatitis C Patients bms.com ↗ |
| 2011-03-07 | Bristol-Myers Squibb | Results New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress 2011 bms.com ↗
Pegylated Interferon-Lambda (PEGIFN-λ) shows superior viral response with improved safety and tolerability versus PEGIFNα-2A in HCV patients (G1/2/3/4): EMERGE Phase IIb through week 12 |
| 2006-10-27 | Vertex Pharmaceuticals Incorporated | Results New Data for Investigational Hepatitis C Drug Telaprevir (VX-950) to be Presented at AASLD Meeting vrtx.com ↗
Clinical investigators will also report that some of these patients have stopped therapy, and that a proportion of them continued to have undetectable HCV RNA after stopping therapy. |
All press releases naming this drug 6 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon-α2a | “Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in...” PMID 26453773 ↗ Oct 20154“Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C.” PMID 23428875 ↗ Feb 2013 |
| Known as | PEG-interferon alfa-2a | “PEG-interferon alfa-2a and ribavirin.” NCT00881582 ↗ |
| Known as | PegIFNα-2a | “We assessed the safety and efficacy of PegIFNα-2a and ribavirin (RBV) combination therapy in HCV-infected RT recipients.” PMID 23428875 ↗ Feb 2013 |
| Known as | Pegylated interferon alfa-2a | “Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose” NCT00881582 ↗ |
| Route | Subcutaneous | “Peg-IFN 180 µg administered via subcutaneous injection once weekly” NCT01277601 ↗ |